Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q1 FY25 Earnings Presentation
22 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Aug 8, 2024
Slide 1: Company Presentation cover letter to NSE
August 8, 2024 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Sub: Company Presentation Enclosed is Company’s presentation on financial results for the quarter ended on J
Slide 2: JB Pharma – Q1 FY25 Investor Presentation
JB Pharma – Q1 FY25 Investor Presentation August 8, 2024 www.jbpharma.com jbpharma/
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: JB Pharma – Looking ahead
> Synergistic acquisitions 5.) productivity Domestic outperformer @® g Gl leader A . Strong FCF GOOD PEOPLE 5 Consistency of delivery 9 for C000 HEATH _ Dosage ols op Global regulatory approvals Medicated/Herbal lozenges a p : a Leadership Key therapies Pillar Brands “J B PHARMA ** Dosage forms Stat
Slide 5: Top 5 brands, 40+ years of operations
47 5 40+ Top 5 Brands among top 300 brands Regulated/semi-regulated Global manufacturer of Years of operations with (IQVIA MAT Mar’24 data), markets of presence through medicated/herbal lozenges consistent track record across contributing over 50% of direct operations and representing a substantial
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 27.0% 42% 25.0% 24.3% 21.3% 3,484 18.6% 3,149 29% 27% 15.4% 24% # 2,424 22% 21% 2,043 1,643 1,775 15% 25% 1,413 19% 18% 19% 17% 449 386 410 553 13% 139 194 272 10% FY18 FY19 FY20 FY21 F
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities 40 8 + 10 State of the Art Global Dosage forms manufacturing Regulatory produced facilities Accreditations Tablets Capsules Liquids IV Ampules Infusions Vials Ointments Cold Lozenges Sips Rubs 6
Slide 8: Q1 FY25 Business Performance
Q1 FY25 Business Performance
Slide 9: CEO’s Message
CEO’s Message “Our overall performance in the first “ quarter has been robust. We have reached a new milestone of INR 1,000 crores in quarterly sales for the first time during any quarter, with improvement across all parameters — revenue, gross profit, operating profit and operating profit margin. S
Slide 10: Results Overview: Q1 FY25 vs Q1 FY24
Results Overview: Q1 FY25 vs Q1 FY24 Revenues (INR crores) 11% 3,484 3,149 o JB Pharma’s revenue crossed INR 1000 crores in a quarter 12% for the first time • Revenue grew 12% to INR 1004 crores vs INR 896 crores 896 1,004 o Domestic formulations business recorded revenue of INR 595 crores vs INR 48
Slide 11: EBITDA Analysis
EBITDA Analysis INR crores Q1 FY25 Q1 FY24 FY24 FY23 Revenue 1004 896 3484 3149 Reported EBITDA 280 232 897 696 Non Cash ESOP Charge 12 11 42 69 Included in Employee Benefits expense ^Operating EBITDA (excluding ESOP 292 243 939 765 charge) Operating EBITDA margins 29.0% 27.1% 27.0% 24.3% 10 ^Operat
Slide 12: Financial Overview Q1 FY25 vs Q1 FY24
Financial Overview Q1 FY25 vs Q1 FY24 27.0% Op. EBITDA (INR crores) 24.3% 765 939 o Operating EBITDA witnessed YoY improvement of 20% to INR 292 crores. Operating EBITDA margin stood at 29.0% (YoY 29.0% improvement of 190 basis points) o Despite limited margin on the ophthalmology portfolio, gross 2
Slide 13: Domestic Business Q1 FY25 vs Q1 FY24
Domestic Business Q1 FY25 vs Q1 FY24 o Domestic business continued its momentum and Domestic Formulations (INR crores) registered YoY growth of 22% to INR 595 crores • Excluding ophthalmology portfolio, domestic 22% business grew 13% o JB Pharma gained a rank to #21 in IPM as per IQVIA MAT June’24 d
Slide 14: JB Pharma: Now Ranks #21 in the Indian Pharmaceuticals Market
JB Pharma: Now Ranks #21 in the Indian Pharmaceuticals Market Among top 25, JB is one of the One of the fastest growing fastest growing pharma Leadership position company among the Top 25 in company in the IPM in the covered markets the IPM as per IQVIA MAT 10% Vs IPM growth 35% + share in 6 molecul
Slide 15: 5 Brands now Rank among the Top 150 in the IPM
5 Brands now Rank among the Top 150 in the IPM MAT June’23 Value Sales* MAT June’24 Value Sales* MAT June’23 Rank MAT June’24 Rank CILACAR 343 410 #40 #30 RANTAC 357 364 #35 #38 METROGYL 196 212 #145 #112 CILACAR-T 147 187 #178 #142 NICARDIA 156 180 #162 #149 14 All data as per IQVIA *INR crores
Slide 16: Brand Franchises Getting Stronger
Brand Franchises Getting Stronger INR 444 crores INR 681 crores INR 359 INR 447 INR 258 crores INR 319 IQVIA MAT June’22 IQVIA MAT June’24 crores IQVIA MAT June’22 IQVIAcrores MAT June’24 IQVIA MAT June’22 crores IQVIA MAT June’24 CAGR: 24% CAGR: 12% CAGR: 11% CILACAR T RANTAC DOM METROGYL P CILACAR
Slide 17: Sporlac – Now an INR 100+ crores Brand
Sporlac – Now an INR 100+ crores Brand 20% Sporlac Sales 101 94 70 64 * o Sporlac crossed INR 100 crores of sales as per IQVIA MAT June’24 data • Brand grew at 3 years CAGR of 20% MAT Feb'22 MAT June'22 MAT June'23 MAT June'24 (IQVIA MAT June’24 vs MAT June’22 data) o The brand has gained consistent
Slide 18: International Business Q1 FY25 vs Q1 FY24
International Business Q1 FY25 vs Q1 FY24 o International business revenue remained flat at INR 409 crores vs INR 407 crores 1% 407 409 5% o International formulations business registered YoY growth of 5% to INR 290 crores 290 275 • Russia and RoW business delivered strong growth • South Africa tend
Slide 19: Q1 FY25 Financial Performance (Consolidated)
Q1 FY25 Financial Performance (Consolidated) Particulars Q1 FY25 Q1 FY24 YoY Growth FY24 FY23 YoY Growth Revenue from Operations 1004 896 12% 3484 3149 11% Cost of Goods Sold 340 310 10% 1182 1168 1% Gross Profit 665 586 13% 2302 1981 16% Gross Profit Margins 66.2% 65.4% 66.1% 62.9% Employee Benefit
Slide 20: JB Pharma – Looking ahead
JB Pharma – Looking ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform Sustained growth momentum in International market growth driven by business CDMO business to maintain growth momentum aided by new Big bra
Slide 21: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one contact: of the fastest growing pharmaceutical companies in India and a leading player in the hypertension Narayan Saraf, Chief Financial Officer segment. Bes
Slide 22: Thank you
GOOD PEOPLE _for GOOD HEALTH Thank you CF Xin) www.jbpharma.com
J. B. Chemicals & Pharmaceuticals — Q1 FY25 Earnings Presentation on 6ix